GlassScriptPhysician profile
Matthew S Naegle
NPI 1154850477
$1,285.68
in general payments reported to CMS, 2019-2025
34 companies · $150 in 2025
The $150 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $56.02 · 2021: $382 · 2022: $387 · 2023: $200 · 2024: $112 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $126.27 | 2021-2025 | Bexsero, Penmenvy, Arexvy |
| Amarin Pharma, INC. | $101.17 | 2020-2022 | |
| Cranial Technologies, INC | $83.28 | 2021-2024 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $65.18 | 2020-2023 | Flumist Quadrivalent |
| Merck Sharp & Dohme LLC | $61.09 | 2021-2023 | Rotateq, Gardasil 9, Vaxelis |
| Pfizer INC. | $57.37 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.20 | 2021-2023 | Jardiance, Synjardy |
| Sobi, INC | $53.97 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.81 | 2020-2022 | |
| Organon LLC | $51.17 | 2022-2023 | Nexplanon |
| Biomerieux INC | $44.00 | 2025 | Biofire Spotfire Control Station |
| Lilly USA, LLC | $43.04 | 2021-2023 | Jardiance, Baqsimi |
| Takeda Pharmaceuticals U.S.A., INC. | $37.66 | 2022-2023 | Trintellix |
| Nestle Healthcare Nutrition INC. | $35.24 | 2021 | |
| Dynavax Technologies Corporation | $33.12 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $32.86 | 2024 | Apretude |
| Genentech USA, INC. | $31.22 | 2021 | |
| Lucid Diagnostics INC. | $30.62 | 2022 | |
| Janssen Pharmaceuticals, INC | $29.46 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $25.32 | 2022 | |
| Krystal Biotech INC | $22.79 | 2024 | Vyjuvek |
| Treace Medical Concepts, INC. | $22.23 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $19.56 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.52 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.43 | 2022 | |
| Abbvie INC. | $17.53 | 2025 | |
| Avanir Pharmaceuticals, INC. | $16.85 | 2022 | |
| Currax Pharmaceuticals LLC | $15.60 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.83 | 2021 | |
| Eisai INC. | $14.09 | 2021 | |
| Boston Scientific Corporation | $13.92 | 2023 | Wavewriter Alpha Prime 16 |
| Qiagen, LLC | $13.39 | 2020 | |
| Sanofi Pasteur INC. | $13.17 | 2022 | |
| Tris Pharma INC | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Naegle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.